In short
This article discusses a clinical trial investigating the effectiveness of two treatments, 2LEBV® and 2LXFS®, in reducing fatigue and other symptoms associated with Epstein-Barr Virus (EBV) infection. The study aims to compare these treatments against a placebo in a randomized, double-blind setting, focusing on patients aged 12 and older who experience significant fatigue and other EBV-related symptoms.
At a glance
- Study Type
- Randomized, placebo-controlled, double-blind clinical trial
- Treatments
- 2LEBV® and 2LXFS®/2LEBV® compared to placebo
- Main Condition
- Epstein-Barr Virus (EBV) infection with fatigue
- Primary Outcome
- Fatigue severity at 6 months (end of treatment)
- Secondary Outcomes
- Other fatigue dimensions, EBV-related symptoms, lymphocyte typing, antibody levels
- Participant Age
- 12 years and older
- Key Inclusion Criteria
- Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
- Key Exclusion Criteria
- Recent homeopathic treatments, immunosuppressive therapy, severe immunodeficiency
- Follow-up Duration
- 12 months
What is RIBONUCLEIC ACID K30?
RIBONUCLEIC ACID K30 is one of the active substances in a medication called 2LXFS. This medication is being studied as a potential treatment for people infected with the Epstein-Barr Virus (EBV) who are experiencing significant fatigue. Ribonucleic acid, also known as RNA, is a type of molecule that plays a crucial role in various biological processes in our bodies.
Epstein-Barr Virus and Fatigue
The Epstein-Barr Virus is a common virus that can cause various symptoms, including severe fatigue. When you're infected with EBV, your body's immune system fights the virus, which can lead to feelings of exhaustion that last for a long time. This fatigue can significantly impact your daily life and overall well-being.
Clinical Trial Overview
A clinical trial is currently being conducted to evaluate how effective 2LXFS (which contains RIBONUCLEIC ACID K30) is in reducing fatigue in patients with EBV infection. This study is: Randomized: Participants are randomly assigned to different groups Placebo-controlled: Some participants receive the actual medication, while others receive a placebo (a substance with no active ingredients) Double-blind: Neither the participants nor the researchers know who is receiving the actual medication or the placebo
Potential Benefits
The main goal of this study is to see if 2LXFS can help reduce the severity of fatigue in people with EBV infection. Researchers are also looking at other potential benefits, including: Improvements in other symptoms related to EBV infection Changes in the immune system, particularly in the types and numbers of certain immune cells (lymphocytes) Changes in the levels of antibodies (IgG) that your body produces in response to the EBV infection
Who Can Participate?
The study is looking for participants who meet certain criteria: Males or females aged 12 years and older Experiencing significant fatigue for 1 month or more Have at least two other symptoms related to EBV infection (such as fever, sore throat, swollen lymph nodes, etc.) Have a positive blood test for EBV
However, some people may not be able to participate if they: Have previously used 2LXFS or similar treatments Are taking certain medications that affect the immune system Are pregnant or breastfeeding Have certain medical conditions or are undergoing specific treatments
What to Expect During the Trial
If you participate in this trial, you can expect the following: Regular check-ups and evaluations over a period of 12 months Completion of questionnaires about your fatigue and other symptoms Blood tests to check your immune system and antibody levels You'll be given either 2LXFS or a placebo to take as directed
Safety Considerations
As with any medical treatment, there may be potential risks or side effects. The researchers will be closely monitoring all participants for any adverse events throughout the study. It's important to report any unusual symptoms or changes in your health to the study team promptly.
Remember, participating in a clinical trial is voluntary, and you can withdraw at any time. Always discuss with your healthcare provider before deciding to participate in any clinical trial.